HomeAI · summaries
Storia in 20 fonti
FDA approves ‘game-changing’ pancreatic cancer drug
In a late-stage trial, people who got Revolution Medicines’ Rasonque, or daraxonrasib, lived about twice as long as people who got standard care.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Rasonque nabs FDA approval for previously treated metastatic pancreatic adenocarcinoma
The FDA has approved a first-in-class targeted therapy for adults with metastatic pancreatic adenocarcinoma. Daraxonrasib (Rasonque, Revolution Medicines), an RAS inhibitor,…
- ·
forbes.com
FDA Approves Pancreatic Cancer Drug That Could Double Survival Time—What To Know About Rasonque
Rasonque joins a short list of treatment options for one of the country’s deadliest types of cancer.
